Table of Content

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview
4.1. Introduction
4.2. Beta Lactam & Beta Lactamase Inhibitors Market, by Region

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing incidents of infectious diseases
5.1.1.2. Growing demand for over-the-counter drugs
5.1.1.3. Government initiatives to improve supply chain
5.1.2. Restraints
5.1.2.1. High cost of raw materials
5.1.3. Opportunities
5.1.3.1. Technological advances in beta lactam & beta lactamase inhibitor combinations
5.1.3.2. Increasing investments in pharmaceutical research
5.1.4. Challenges
5.1.4.1. Production complexities associated with beta lactam & beta lactamase inhibitors
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of COVID-19
5.5. Cumulative Impact of Russia-Ukraine Conflict
5.6. Cumulative Impact of High Inflation
5.7. Porter’s Five Forces Analysis
5.7.1. Threat of New Entrants
5.7.2. Threat of Substitutes
5.7.3. Bargaining Power of Customers
5.7.4. Bargaining Power of Suppliers
5.7.5. Industry Rivalry
5.8. Value Chain & Critical Path Analysis
5.9. Regulatory Framework
5.10. Client Customization

6. Beta Lactam & Beta Lactamase Inhibitors Market, by Drug Class
6.1. Introduction
6.2. Carbapenem
6.3. Cephalosporins
6.4. Monobactam
6.5. Penicillin

7. Beta Lactam & Beta Lactamase Inhibitors Market, by Disease
7.1. Introduction
7.2. Blood Stream Infection
7.3. Complicated Intra-Abdominal Infections (cIAI)
7.4. Complicated Urinary Tract Infection (cUTI)
7.5. Nosocomial Pneumonia
7.6. Respiratory Infection
7.7. Skin Infection
7.8. Urinary Tract Infection (excluding cUTI)

8. Beta Lactam & Beta Lactamase Inhibitors Market, by Route of Administration
8.1. Introduction
8.2. Intravenous
8.3. Oral

9. Americas Beta Lactam & Beta Lactamase Inhibitors Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Beta Lactam & Beta Lactamase Inhibitors Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Beta Lactam & Beta Lactamase Inhibitors Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. AbbVie Inc.
13.1.2. AstraZeneca PLC
13.1.3. Aurobindo Pharma Limited
13.1.4. Bio-Rad Laboratories, Inc.
13.1.5. Bristol-Myers Squibb Company
13.1.6. Centrient Pharmaceuticals Netherlands B.V.
13.1.7. Creative Diagnostics
13.1.8. F. Hoffmann-La Roche AG
13.1.9. GlaxoSmithKline PLC
13.1.10. Marubeni Corporation
13.1.11. Melinta Therapeutics, LLC
13.1.12. Merck KGaA
13.1.13. Novartis AG
13.1.14. Pfizer Inc.
13.1.15. Protech Telelinks
13.1.16. Qpex Biopharma, Inc.
13.1.17. Sanofi SA
13.1.18. SciClone Pharmaceuticals (Holdings) Limited
13.1.19. Sumitomo Pharma Co., Ltd.
13.1.20. Teva Pharmaceutical Industries Ltd.
13.1.21. Thermo Fisher Scientific Inc.
13.1.22. TOKU-E
13.1.23. Venatorx Pharmaceuticals, Inc.
13.1.24. Viatris Inc.
13.1.25. Zai Lab Limited
13.2. Key Product Portfolio

14. Appendix
14.1. Discussion Guide
14.2. License & Pricing



List of Figures

FIGURE 1. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET RESEARCH PROCESS
FIGURE 2. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2022 VS 2030
FIGURE 3. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
FIGURE 5. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY REGION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 6. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET DYNAMICS
FIGURE 7. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2022 VS 2030 (%)
FIGURE 8. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 9. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2022 VS 2030 (%)
FIGURE 10. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 11. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2022 VS 2030 (%)
FIGURE 12. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 14. AMERICAS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY STATE, 2022 VS 2030 (%)
FIGURE 16. UNITED STATES BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 21. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2022
FIGURE 22. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SHARE, BY KEY PLAYER, 2022

List of Tables

TABLE 1. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018–2022
TABLE 3. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 6. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CARBAPENEM, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CEPHALOSPORINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY MONOBACTAM, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PENICILLIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 11. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY BLOOD STREAM INFECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI), BY REGION, 2018-2030 (USD MILLION)
TABLE 13. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COMPLICATED URINARY TRACT INFECTION (CUTI), BY REGION, 2018-2030 (USD MILLION)
TABLE 14. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY NOSOCOMIAL PNEUMONIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY RESPIRATORY INFECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SKIN INFECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY URINARY TRACT INFECTION (EXCLUDING CUTI), BY REGION, 2018-2030 (USD MILLION)
TABLE 18. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 19. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. AMERICAS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 22. AMERICAS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 23. AMERICAS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 24. AMERICAS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 25. ARGENTINA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 26. ARGENTINA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 27. ARGENTINA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 28. BRAZIL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 29. BRAZIL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 30. BRAZIL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 31. CANADA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 32. CANADA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 33. CANADA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 34. MEXICO BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 35. MEXICO BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 36. MEXICO BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 37. UNITED STATES BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 38. UNITED STATES BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 39. UNITED STATES BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 40. UNITED STATES BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 41. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 42. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 43. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 44. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 45. AUSTRALIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 46. AUSTRALIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 47. AUSTRALIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 48. CHINA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 49. CHINA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 50. CHINA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 51. INDIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 52. INDIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 53. INDIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 54. INDONESIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 55. INDONESIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 56. INDONESIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 57. JAPAN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 58. JAPAN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 59. JAPAN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 60. MALAYSIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 61. MALAYSIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 62. MALAYSIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 63. PHILIPPINES BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 64. PHILIPPINES BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 65. PHILIPPINES BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 66. SINGAPORE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 67. SINGAPORE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 68. SINGAPORE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 69. SOUTH KOREA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 70. SOUTH KOREA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 71. SOUTH KOREA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 72. TAIWAN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 73. TAIWAN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 74. TAIWAN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 75. THAILAND BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 76. THAILAND BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 77. THAILAND BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 78. VIETNAM BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 79. VIETNAM BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 80. VIETNAM BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 82. EUROPE, MIDDLE EAST & AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 83. EUROPE, MIDDLE EAST & AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 84. EUROPE, MIDDLE EAST & AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 85. DENMARK BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 86. DENMARK BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 87. DENMARK BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 88. EGYPT BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 89. EGYPT BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 90. EGYPT BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 91. FINLAND BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 92. FINLAND BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 93. FINLAND BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 94. FRANCE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 95. FRANCE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 96. FRANCE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 97. GERMANY BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 98. GERMANY BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 99. GERMANY BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 100. ISRAEL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 101. ISRAEL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 102. ISRAEL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 103. ITALY BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 104. ITALY BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 105. ITALY BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 106. NETHERLANDS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 107. NETHERLANDS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 108. NETHERLANDS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 109. NIGERIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 110. NIGERIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 111. NIGERIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 112. NORWAY BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 113. NORWAY BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 114. NORWAY BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 115. POLAND BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 116. POLAND BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 117. POLAND BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 118. QATAR BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 119. QATAR BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 120. QATAR BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 121. RUSSIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 122. RUSSIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 123. RUSSIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 124. SAUDI ARABIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 125. SAUDI ARABIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 126. SAUDI ARABIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 127. SOUTH AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 128. SOUTH AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 129. SOUTH AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 130. SPAIN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 131. SPAIN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 132. SPAIN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 133. SWEDEN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 134. SWEDEN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 135. SWEDEN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 136. SWITZERLAND BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 137. SWITZERLAND BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 138. SWITZERLAND BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 139. TURKEY BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 140. TURKEY BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 141. TURKEY BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 142. UNITED ARAB EMIRATES BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 143. UNITED ARAB EMIRATES BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 144. UNITED ARAB EMIRATES BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 145. UNITED KINGDOM BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 146. UNITED KINGDOM BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 147. UNITED KINGDOM BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 148. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2022
TABLE 149. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SHARE, BY KEY PLAYER, 2022
TABLE 150. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET LICENSE & PRICING